Literature DB >> 30648314

The Chang Gung Research Database-A multi-institutional electronic medical records database for real-world epidemiological studies in Taiwan.

Shih-Chieh Shao1,2, Yuk-Ying Chan3, Yea-Huei Kao Yang2, Swu-Jane Lin4, Ming-Jui Hung5, Rong-Nan Chien6, Chi-Chun Lai7, Edward Chia-Cheng Lai2,8.   

Abstract

PURPOSE: The Chang Gung Research Database (CGRD), the largest multi-institutional electronic medical records (EMR) collection in Taiwan, provides good access for researchers to efficiently use the standardized patient-level data. This study evaluates the capacity and representativeness of the CGRD to promote secondary use of EMR data for clinical research with more accurate estimates.
METHODS: The National Health Insurance Research Database (NHIRD) which covers over 99.9% of the Taiwanese population served as the comparator in this study. We compare the data components of the CGRD with the NHIRD, including records for health care facilities, patients, diagnoses, drugs, and procedures. Using the chi-square test, we compared the distributions of age categories and sex of patients, and the rates of their health conditions between NHIRD and CGRD based on the year 2015.
RESULTS: The CGRD contains more clinical information such as pathological and laboratory results than the NHIRD. The CGRD includes 6.1% of outpatients and 10.2% of hospitalized patients from the NHIRD. We found the CGRD includes more elderly outpatients (23.5% vs 12.5%) and pediatric inpatients (19.7% vs 14.4%) compared with the NHIRD. We found patients' sex distributions were similar between CGRD and NHIRD, but coverage rates of severe conditions, such as cancer, were higher than other health conditions in CGRD.
CONCLUSIONS: The CGRD could serve as the basis for accurate estimates in medical studies. However, researchers should pay special attention to selection biases since patients' characteristics from CGRD differ from those of the national database.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Chang Gung Research Database; electronic health record; electronic medical record; pharmacoepidemiology; real-world evidence

Mesh:

Year:  2019        PMID: 30648314     DOI: 10.1002/pds.4713

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  66 in total

1.  Incidence and consequences of resuming oral anticoagulant therapy following hematuria and risks of ischemic stroke and major bleeding in patients with atrial fibrillation.

Authors:  Chun-Li Wang; Victor Chien-Chia Wu; Yu-Tung Huang; Yu-Ling Chen; Pao-Hsien Chu; Chang-Fu Kuo; Ming-Shien Wen; Shang-Hung Chang
Journal:  J Thromb Thrombolysis       Date:  2021-01       Impact factor: 2.300

2.  Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Chi Chuang; Fu-Chih Hsiao; Yu-Wen Cheng; Chia-Pin Lin; Ying-Chang Tung; Chia-Tung Wu; Ching-Yen Chen; Pao-Hsien Chu
Journal:  Acta Cardiol Sin       Date:  2022-09       Impact factor: 1.800

Review 3.  Harnessing Electronic Medical Records in Cardiovascular Clinical Practice and Research.

Authors:  Pishoy Gouda; Justin Ezekowitz
Journal:  J Cardiovasc Transl Res       Date:  2022-09-14       Impact factor: 3.216

4.  Ivabradine in heart failure patients with reduced ejection fraction and history of paroxysmal atrial fibrillation.

Authors:  Yu-Sheng Lin; Jeng-Yu Jan; Jung-Jung Chang; Ming-Shyan Lin; Teng-Yao Yang; Po-Chang Wang; Mien-Cheng Chen
Journal:  ESC Heart Fail       Date:  2022-05-12

5.  Validation of Diagnostic Codes to Identify Carbon Monoxide Poisoning in Taiwan's Claims Data.

Authors:  Min-Ying Chiang; Shih-Chieh Shao; Shu-Chen Liao
Journal:  Front Pharmacol       Date:  2022-06-15       Impact factor: 5.988

6.  Changing trends in dialysis modalities utilization and mortality in children, adolescents and young adults with acute kidney injury, 2010-2017.

Authors:  You-Lin Tain; Hsiao-Ching Kuo; Chien-Ning Hsu
Journal:  Sci Rep       Date:  2021-06-04       Impact factor: 4.379

7.  The risk of consequent nephropathy following initial weight loss in diabetic patients treated with sodium glucose cotransporter 2 inhibitors.

Authors:  Yi-Hsin Chan; Shao-Wei Chen; Tze-Fan Chao; Yi-Wei Kao; Chien-Ying Huang; Pao-Hsien Chu
Journal:  Cardiovasc Diabetol       Date:  2021-08-16       Impact factor: 9.951

8.  Clinical Outcomes and Adverse Effects in Septic Patients with Impaired Renal Function Who Received Different Dosages of Cefoperazone-Sulbactam.

Authors:  Chien-Hsiang Tai; Hung-Jen Tang; Chen-Hsiang Lee
Journal:  Antibiotics (Basel)       Date:  2022-03-29

9.  Application of Healthcare 'Big Data' in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN).

Authors:  Jenni Ilomäki; J Simon Bell; Adrienne Y L Chan; Anna-Maija Tolppanen; Hao Luo; Li Wei; Edward Chia-Cheng Lai; Ju-Young Shin; Giorgia De Paoli; Romin Pajouheshnia; Frederick K Ho; Lorenna Reynolds; Kui Kai Lau; Stephen Crystal; Wallis C Y Lau; Kenneth K C Man; Ruth Brauer; Esther W Chan; Chin-Yao Shen; Ju Hwan Kim; Terry Y S Lum; Sirpa Hartikainen; Marjaana Koponen; Evelien Rooke; Marloes Bazelier; Olaf Klungel; Soko Setoguchi; Jill P Pell; Sharon Cook; Ian C K Wong
Journal:  CNS Drugs       Date:  2020-09       Impact factor: 5.749

10.  Characteristics of ischemic stroke and intracranial hemorrhage in patients with nephrotic syndrome.

Authors:  Wen-Yi Huang; Chun-Wei Chang; Chiung-Mei Chen; Kuan-Hsing Chen; Chien-Hung Chang; Hsiu-Chuan Wu; Kuo-Hsuan Chang
Journal:  BMC Nephrol       Date:  2021-06-05       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.